QIUQIANG CHEN^1,*, XUEJUN GUO², WENXUE MA^3,*

Oncology Research, Vol.32, No.1, pp. 49-60, 2024, DOI:10.32604/or.2023.042383

Abstract Cancer immunotherapy has emerged as a promising strategy for the treatment of cancer, with the tumor microenvironment (TME) playing a pivotal role in modulating the immune response. CD47, a cell surface protein, has been identified as a crucial regulator of the TME and a potential therapeutic target for cancer therapy. However, the precise functions and implications of CD47 in the TME during immunotherapy for cancer patients remain incompletely understood. This comprehensive review aims to provide an overview of CD47’s multifaced role in TME regulation and immune evasion, elucidating its impact on various types of immunotherapy outcomes, including checkpoint inhibitors and… More > Graphic Abstract

XUEFENG WANG^1,#, SICONG JIANG^2,#, XINHONG ZHOU³, XIAOFENG WANG⁴, LAN LI⁵, JIANJUN TANG^1,*

Oncology Research, Vol.31, No.5, pp. 697-714, 2023, DOI:10.32604/or.2023.029458

Abstract Background: Pancreatic cancer is associated with high mortality and is one of the most aggressive of malignancies, but studies have not fully evaluated its molecular subtypes, prognosis and response to immunotherapy of different subtypes. The purpose of this study was to explore the molecular subtypes and the key genes associated with the prognosis of pancreas cancer patients and study the clinical phenotype, prognosis and response to immunotherapy using single-cell seq data and bulk RNA seq data, and data retrieved from GEO and TCGA databases. Methods: Single-cell seq data and bioinformatics methods were used in this study. Pancreatic cancer data were… More >

WENHAO XU^1,#, HAOMING LI^2,#, YASIR HAMEED³, MOSTAFA A. ABDEL-MAKSOUD⁴, SAEEDAH MUSAED ALMUTAIRI⁴, AYMAN MUBARAK⁴, MOHAMMED AUFY⁵, WAEL ALTURAIKI⁶, ABDULAZIZ J. ALSHALANI⁶, AYMAN M. MAHMOUD^7,*, CHEN LI^8,*

Oncology Research, Vol.31, No.5, pp. 819-831, 2023, DOI:10.32604/or.2023.029414

Abstract N6-methyladenosine methylation (m6A) is a common type of epigenetic alteration that prominently affects the prognosis of tumor patients. However, it is unknown how the m6A regulator affects the tumor microenvironment (TME) cell infiltration in adrenocortical carcinoma (ACC) and how it affects the prognosis of ACC patients yet. The m6A alteration patterns of 112 ACC patients were evaluated, furthermore, the association with immune infiltration cell features was investigated. The unsupervised clustering method was applied to typify the m6A alteration patterns of ACC patients. The principal component analysis (PCA) technique was taken to create the m6A score to assess the alteration pattern… More >

DONGJIE SUN^1,2, CHI ZHANG^3,*

Oncology Research, Vol.31, No.5, pp. 753-767, 2023, DOI:10.32604/or.2023.029287

Abstract Lung adenocarcinoma (LUAD) is the leading cause of cancer-related deaths, accounting for over a million deaths worldwide annually. Immunogenic cell death (ICD) elicits an adaptive immune response. However, the role of ICD-related long noncoding RNAs (lncRNAs) in LUAD is unknown. In this study, we investigated the characteristics of the tumor microenvironment in LUAD, the prognostic significance of ICD-related lncRNAs, and the half-maximal inhibitory concentration (IC50) of possible chemotherapeutic drugs. We sorted prognostic lncRNAs using univariate Cox regression and constructed a risk signature based on them. We then confirmed the model’s accuracy and generated a nomogram. Additionally, we performed immune microenvironment… More > Graphic Abstract

HANYANG GUAN^1,#, YUE WU^2,#, LU LI^3,#, YABING YANG¹, SHENGHUI QIU¹, ZHAN ZHAO¹, XIAODONG CHU¹, JIASHUAI HE¹, ZUYANG CHEN¹, YIRAN ZHANG¹, HUI DING¹, JINGHUA PAN^1,*, YUNLONG PAN^1,*

Oncology Research, Vol.31, No.4, pp. 437-448, 2023, DOI:10.32604/or.2023.029924

Abstract Neoantigen-targeted immunotherapy is a rapidly advancing field that holds great promise for treating cancer. The recognition of antigens by immune cells is a crucial step in tumor-specific killing, and neoantigens generated by mutations in cancer cells possess high immunogenicity and are selectively expressed in tumor cells, making them an attractive therapeutic target. Currently, neoantigens find utility in various domains, primarily in the realm of neoantigen vaccines such as DC vaccines, nucleic acid vaccines, and synthetic long peptide vaccines. Additionally, they hold promise in adoptive cell therapy, encompassing tumor-infiltrating cells, T cell receptors, and chimeric antigen receptors which are expressed by… More > Graphic Abstract

WUYAO LIU, CHANGBAO QU, XIAOLU WANG^*

Oncology Research, Vol.31, No.4, pp. 543-567, 2023, DOI:10.32604/or.2023.029563

Abstract The high immune infiltration and heterogeneity of the microenvironment in clear cell renal cell carcinoma (ccRCC) result in the variability of prognosis and clinical response. While PANoptosis has strong immunogenicity and is worthy of further study. In this study, data from The Cancer Genome Atlas database was used to obtain immune-related PANoptosis lncRNAs with prognostic value. Subsequently, the role of these lncRNAs in cancer immunity, progression and the therapeutic response was analyzed, and a new prediction model was constructed. Additionally, we further explored the biological value of PANoptosis-related lncRNAs using single-cell data from the Gene Expression Omnibus database. PANoptosis-associated lncRNAs… More >

LETIAN JIN, HETING CHEN, QI RUAN, RUI LIU, YIFENG FAN, XIUFANG XU, DAJIANG WANG^*, JIAHUI LU^*

BIOCELL, Vol.47, No.7, pp. 1483-1498, 2023, DOI:10.32604/biocell.2023.028457

Abstract During the chemotherapy of tumors, the cytotoxic effect of drugs is vital to kill tumor cells, and the delivery of a chemotherapeutic agent is of great importance for optimal therapeutic effects. The high in vivo clearance rate and low delivery efficiency of conventional chemotherapeutic agents affect the therapeutic effect. In recent years, the responsive drug delivery nanosystem has received increasing concern owing to its excellent biocompatibility, stable delivery performance, and controlled drug release strategies. To lucidly explain the cytocidal and immunotherapeutic effects of such responsive nanosystems in breast cancer, this review discusses the various stimuli and responses of drug-loaded liposomal… More >

JIAHENG XIE^1,#, MENGMENG OU^1,#, PAN YU^1,#, DAN WU^2,#, QIKAI TANG³, YUAN CAO⁴, JING HANG⁵, LU YIN¹, TINGHONG XIANG¹, MING WANG^1,*, JINGPING SHI^1,*

Oncology Research, Vol.31, No.3, pp. 389-403, 2023, DOI:10.32604/or.2023.029274

Abstract Purpose: To screen potential tumor antigens for melanoma vaccine development and identify different immune subtypes. Methods: Transcriptional data (HTSEQ-FPKM) and clinical information of a 472 Melanoma cohort GDC TCGA Melanoma (SKCM) were downloaded from the UCSC XENA website (). Subsequently, transcriptome data and clinical information of 210 melanoma cohort GSE65904 were downloaded from Gene Expression Omnibus (GEO), a large global public database. All the transcriptome expression data matrices were log2 transformed for subsequent analysis. GEPIA, TIMER, and IMMPORT databases are also used for analysis. Cell function experiments were performed to validate the role of the IDO1 gene in melanoma cell… More >

LAZAR S. POPOVIC^1,2,*, GORANA MATOVINA-BRKO¹, MAJA POPOVIC^1,2, KEVIN PUNIE³, ANA CVETANOVIC^4,5, MATTEO LAMBERTINI^6,7

Oncology Research, Vol.31, No.3, pp. 221-238, 2023, DOI:10.32604/or.2023.028525

Abstract Triple-negative breast cancer (TNBC) is a disease with often an aggressive course and a poor prognosis compared to other subtypes of breast cancer. TNBC accounts for approximately 10%–15% of all diagnosed breast cancer cases and represents a high unmet need in the field. Up to just a few years ago, chemotherapy was the only systemic treatment option for this subtype (1). To date, TNBC is considered a heterogeneous disease. One of the existing classifications is based on the analysis of mRNA expression in 587 TNBC cases, in which Lehman et al. proposed six subtypes of TNBC as follows: two basal-like… More > Graphic Abstract

LU LIU^1,2, BIN XIE^1,2, WEI ZHU^1,2, QIUYAN HE^1,2, JIANHUA ZHOU^1,2, SHUANG LIU³, YONGGUANG TAO⁴, DESHENG XIAO^1,2,*

Oncology Research, Vol.31, No.3, pp. 275-286, 2023, DOI:10.32604/or.2023.028227

Abstract Background: Lung cancer is one of the most lethal cancers worldwide, but studies have shown that the higher the expression of programmed cell death protein 1 ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC), the more likely it will benefit from anti-PD-L1 immunotherapy. The purpose of our study was to collect and analyze abundant clinical samples in order to provide evidence for clinicians and patients who might consider anti-PD-L1 immunotherapy while jointly formulating treatment plans. Methods: On the one hand, we obtained cases from The Cancer Genome Atlas (TCGA) database, including 498 lung squamous cell cancer (LUSC) patients and… More >